| DRUG PROVING |
|
| Year : 2008 | Volume
: 2
| Issue : 3 | Page : 10-14 |
|
|
Ficus Religiosa: A multicentric double blind Homoeopathic Pathogenetic Trial (drug proving) carried out by CCRH*
NR Dey1, KC Das2, Yogendra Rai3, VA Siddiqui4, Rajpal Singh4
1 Drug Proving Research Unit, Kolkata, West Bengal, India
2 Drug Proving Research Unit, Midnapore, West Bengal, India
3 Drug Proving Research Unit, Ghaziabad, Uttar Pradesh, India
4 Central Council for Research in Homoeopathy, New Delhi, India
Correspondence Address:
N R Dey
Central Council for Reaserch in Homoeopathy, 61-65, Institutional Area, Opp. D-Block, Janakpuri, New Delhi-110058
India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Objective: Objective of the study was to elicit the pharmacodynamic response of the drug, Ficus religiosa on healthy human beings in non-toxic doses.
Methodology: Drug was proved through a double-blind method and was a multi-centric study. Trial drug was proved in two potencies (30C and 200C) on 24 volunteers who were selected and declared apparently healthy during their pre-trial medical examination by specialists. The volunteers took 56 doses of each of the two potencies in three stages including one control stage for a varying period. The symptoms generated during the trial period were noted by the volunteers and elaborated and cross examined by the Proving Masters. The data obtained from different centers were compiled at proving-cum-data processing cell at CCRH headquarters after decoding the drug.
Observation: Out of the 17 volunteers who were on actual drug trial, 11 manifested symptoms. Drug was able to produce symptoms in each potency more or less on every part of the body. Some of the symptoms have been reproved which are mentioned in the fragmentary provings published in different literatures.
Conclusion: Symptoms appeared (new and reproved) during the proving trial will add to the literature available on the drug and benefit the research scholars and clinicians. This also needs verification through clinical application in different clinical conditions. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
